PageArticles 1 of 32 in PresS. Am J Physiol Gastrointest Liver Physiol (October 25, 2007). doi:10.1152/ajpgi.00371.2007
Camilleri
1
L:\c\c\man\FAAHGenEndocannabinoidPhenotypeFGIDTransit-AJPhysiol-without figs-final-10-18-07.doc and L:\c\c\man\faahgenendocannabinoid Fig 1.tif and pdf L:\c\c\man\faah_revised_figs2-4\revised Fig 2.tif and pdf L:\c\c\man\faah_revised_figs2-4\revised Fig 3.tif and pdf L:\c\c\man\faah_revised_figs2-4\revised Fig 4.tif and pdf 10-18-07 For publication in American Journal of Physiology
Genetic Variation in Endocannabinoid Metabolism, Gastrointestinal Motility and Sensation Michael Camilleri, M.D. Paula Carlson, B.S. Sanna McKinzie, M.S. April Grudell, M.D. Irene Busciglio, B.S. Duane Burton Kari Baxter Michael Ryks Alan R Zinsmeister, Ph.D. # From Clinical Enteric Neuroscience Translational and Epidemiological Research and # Department of Health Sciences Research, Division of Biostatistics College of Medicine, Mayo Clinic, Rochester, MN Running head: Cannabinoid and gastric and colonic functions in humans Acknowledgements: Dr. Camilleri is funded in part by grants RO1-DK54681, RO1DK67071 and K24-DK02638 from National Institutes of Health. We thank Cindy Stanislav for excellent secretarial assistance. Corresponding author:
Michael Camilleri, M.D. Mayo Clinic Charlton 8-110 200 First St. S.W. Rochester, MN 55905 Email:
[email protected]
Copyright 2007 Mayo Foundation
Copyright © 2007 by the American Physiological Society.
Page 2 of 32
Camilleri
2
ABSTRACT (257 words) Background: Cannabinoid agonist inhibits gastrointestinal motility. The endocannabinoid, anandamide, is inactivated by fatty acid amide hydrolase (FAAH). A single nucleotide polymorphism (SNP) in the human FAAH gene (C385A) reduces FAAH expression. Aim: To evaluate associations between FAAH genotype variation and symptom phenotype, gastric emptying and volume, colonic transit and rectal sensation in patients with functional GI disorders (FGID). Methods: 482 FGID patients [Rome II positive, 159 constipation disorders (C-IBS), 184 diarrhea disorders (D-IBS), 86 mixed bowel function (M-IBS), 20 chronic abdominal pain (CAP), 33 functional dyspepsia] and 252 healthy volunteers (HV) underwent questionnaires and studies of phenotype and genotype from 2000-2007: 250 gastric emptying, 210 fasting and postprandial gastric volume, 152 colonic transit and 123 rectal sensation. All had FAAH genotype [CC vs polymorphic (CA/AA)] determined by TaqMan. Results: FAAH genotype distribution of FGID patients and HV did not deviate from Hardy–Weinberg equilibrium. There was a significant association of FAAH genotype with FGID phenotype (overall
2
, p=0.011) and with specific individual phenotypes (p=0.048). Thus,
FAAH CA/AA increases the odds (relative to HV) for D-IBS (p=0.008), M-IBS (p=0.012) and, possibly, CAP (p=0.055). There was a significant association of FAAH CA/AA genotype with accelerated colonic transit in D-IBS (p=0.037). There was no association of FAAH genotype with rectal sensation thresholds or ratings. Conclusions: The association of genetic variation in metabolism of endocannabinoids with symptom phenotype in D-IBS and M-IBS and with faster colonic transit in D-IBS supports the
Page 3 of 32
Camilleri hypothesis that cannabinoid mechanisms may play a role in the control of colonic motility in humans and deserve further study.
Abbreviations in manuscript: CBR = cannabinoid receptors; FAAH = fatty acid amide hydrolase; GC = geometric center of colonic transit; GE = gastric emptying; SNP = single nucleotide polymorphism
3
Page 4 of 32
Camilleri
4 INTRODUCTION
Cannabinoid (CB) receptors are located on cholinergic neurons in the brainstem, stomach and colon. In mice, endocannabinoids acting on myenteric CB1 receptors tonically inhibit colonic propulsion (31). There is evidence of a direct role for cannabinoids in the modulation of motor activity in the human colon. Activation of CB1 receptors coupled to cholinergic motor neurons inhibits excitatory nerve transmission in human colonic circular muscle (21). We have shown that a non-selective CB receptor agonist, dronabinol, inhibits gastric emptying and colonic motility in humans (16,17). CB receptors are also involved in nociception (30,32) and in mediating inflammation (26). Endogenous cannabinoids (or endocannabinoids) include 2-arachidonyl glycerol and anandamide. The latter is inactivated by a fatty acid amide hydrolase (FAAH) in vivo. Anandamide is a partial or full agonist of CB1 receptors. Endocannabinoids are synthesized in postsynaptic neurons and they are released into the synaptic cleft where they function as retrograde messengers (38), binding to the presynaptic CB1 receptor. This, in turn, acts on a range of effectors [e.g. adenyl cyclase, MAP kinase, and K+ and Ca2+ channels] via G
i/o
proteins. The inhibition of adenyl cyclase activity and the
subsequent decrease in cAMP content lead to reduced activity of protein kinases with modulation of ion channels and reduced neurotransmitter release, e.g. acetyl choline. Thus, a non-selective cannabinoid agonist may inhibit contractile activity of the human gastrointestinal tract, and this was demonstrated with the retardation of gastric emptying (17) and the reduction of the tonic and phasic contractile responses of the colon to the ingestion of a meal in humans (16).
Page 5 of 32
Camilleri
5
Cannabinoids have significant effects on visceral and somatic sensation. Their antinociceptive effects involve the brain, spinal cord, and peripheral sensory nerves (reviewed in ref. 30). In acute pain models, anandamide, tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids such as CP 55,940 and WIN 55,212-2 reduce pain induced by chemical, mechanical, and thermal stimuli (30). Similarly, anandamide and cannabinoid ligands are very effective against chronic pain of neuropathic or inflammatory origin in animals (30). These data suggest that CB1 receptors mediate, in part, the nociceptive response to pain in animal models of bowel inflammation (32). Anandamide is also a ligand for TRPV1 receptors, with affinity lower than for CB1 receptors. This suggests that TRPV1 may also be involved in the analgesic effect of endogenous anandamide. Overall, cannabinoids influence motor, sensory and immune functions. These functions have been proposed as mechanisms in the development of functional gastrointestinal disorders (FGID), including irritable bowel syndrome (IBS), functional dyspepsia and chronic (functional) abdominal pain. A single nucleotide polymorphism (SNP) in the human FAAH gene (C385A, rs324420) is the only common SNP in the FAAH gene with a minor allele frequency >5%. In homozygous AA form, the SNP converts a conserved proline residue in FAAH to threonine (P129T), reducing cellular expression of FAAH due to a post-translational mechanism that is not protease-mediated degradation (11). The rationale of this study was based on the potential for genetic variation in anandamide metabolism to influence the synaptic level of the endocannabinoid and, hence, the degree to which presynaptic modulation could influence motor or sensory function, as well as the development of gastrointestinal symptoms. The aim of the study
Page 6 of 32
Camilleri
6
was to evaluate the association of FAAH C385A genotype with symptoms and physiological functions by comparing the odds of carrying the non-wild type genotype and the occurrence of symptoms or abnormal motor or sensory functions in FGID patients compared to normal healthy volunteers. MATERIALS AND METHODS Participants This study assessed 482 FGID patients (Rome II positive, 20 chronic abdominal pain, 184 IBS-D or functional diarrhea, 159 IBS-C or functional constipation, 86 IBSmixed, and 33 dyspepsia) and 252 healthy volunteers recruited to studies of symptom phenotype and genotype from 2000-2007. All participants were recruited from the local population or were residents of the region within 150 miles of Rochester, MN, USA. Participants had been recruited for the original studies (1,7,10,24) by means of letters or public advertisement and had signed informed consent for the respective studies. The inclusion criteria and characteristics of each patient group appear in the original studies; patients fulfilled Rome II criteria. For example, the group with chronic (functional) abdominal pain had abdominal pain of at least 12 weeks duration (not necessarily consecutive) in the absence of bowel dysfunction, in order to differentiate from IBS. In addition, functional dyspepsia patients were identified by upper abdominal pain and discomfort that was related to food ingestion (10). Use of the database from which this analysis was conducted was reviewed and approved by the Mayo Clinic Institutional Review Board, and all participants had given permission for research studies based on medical records and their DNA samples.
Page 7 of 32
Camilleri
7
All participants underwent bowel disease (including somatic symptom) questionnaires, and 250 underwent gastric emptying by scintigraphy, 210 gastric volume measurements during fasting and postprandially by 99mTc-SPECT, 152 colonic transit by scintigraphy, and 126 rectal sensation studies. The validated bowel symptom questionnaire, review of the electronic medical record (SM), or direct physician interview and examination (MC) were used to characterize the sub-type of FGID. The physiological measurements have been used extensively to characterize motor and sensory functions in patients with FGID and to document the effects of pharmacological agents on these functions in health and disease states. Gastrointestinal and Colonic Transit by Scintigraphy An adaptation of our established scintigraphic method was used to measure GI and colonic transit in 152 participants (5,8,14). Briefly, indium-111 (111In) adsorbed on activated charcoal particles was delivered to the colon by means of a methacrylate-coated, delayed-release capsule administered by mouth. The capsule was ingested following an overnight fast. After the capsule emptied from the stomach (documented by its position relative to radioisotopic markers placed on the anterior iliac crests), a radiolabeled meal was ingested. In this meal, technetium-99m ( 99mTc) sulfur colloid was used to label two scrambled eggs that were eaten with one slice of whole wheat bread and one glass of whole milk (300 kcal total). This meal facilitated measurement of gastric and small bowel transit. Subjects ingested standardized meals for lunch and dinner at 4 and 8 hours after the radiolabeled meal, respectively. Abdominal scans were obtained every hour for the first 6 hours (the first 4 hours for the assessment of gastric emptying) and at 8, 24, and
Page 8 of 32
Camilleri
8
48 hours after ingestion of the 111In capsule. The performance characteristics of this test were summarized elsewhere (27). Transit Data Analysis A variable region of interest program was used to quantitate the counts in the stomach and each of four colonic regions: ascending, transverse, descending, and combined sigmoid and rectum. These counts were corrected for isotope decay, tissue attenuation, and downscatter of 111In counts in the 99mTc window. Gastric emptying t1/2 is a measure of the time for 50% of the radiolabeled meal (identifiable by radiolabeled tracer) to empty from the stomach. Overall colonic transit was summarized as the colonic geometric center (GC) at specified times: the GC is the weighted average of counts in the different colonic regions (ascending [AC], transverse [TC], descending [DC], rectosigmoid [RS]) and stool, respectively 1 to 5. Thus, at any time, the proportion of counts in each colonic region is multiplied by its weighting factor as follows: (%AC x 1 + %TC x 2 + %DC x 3 + %RS x 4 + % stool x 5)/100 = geometric center Thus, a higher GC reflects a faster colonic transit. The primary transit endpoints were the gastric emptying t1/2 and colonic geometric center at 24 hours (GC24). In 98 participants, only gastric emptying was performed with the same method and scans obtained over the first 4 hours. Gastric Volume by 99mTc-SPECT Gastric volume was measured in 210 participants using a method developed and validated in our lab (4). We measured the gastric volume during fasting and post-300 ml Ensure® (300 kcal, Ross Labs, Abbott Park, IL). This method uses SPECT (4,25) after
Page 9 of 32
Camilleri
9
intravenous administration of 99mTc-sodium pertechnetate (0.12mCi/kg) which is taken up by the gastric mucosa (29). The camera (SMV-GE, Fairfield, CT) rotates around the thorax and abdomen with the participant lying in the supine position. The stomach was identified in the transaxial SPECT images and separated from background using a semiautomated segmentation algorithm. A three-dimensional rendering of the stomach and its volume was obtained using the AVW 3.0 (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN) image processing libraries. The primary endpoints were fasting and postprandial gastric volume. Rectal Sensation by Barostat These studies were conducted in 123 subjects (91 patients with IBS and 32 healthy controls) who presented to the research center after bowel preparation (Fleet® phosphate enema, self-administered at least 1 hour before reporting to the center) and an overnight fast. The studies were conducted as described in detail elsewhere (13). A catheter with a polyethylene bag (MUI Scientific, Mississauga, Ontario, Canada), was inserted into the rectum so that the middle of the balloon was about 10 cm from the anal verge. Subjects were placed in a semi-prone position and the foot end of the bed was elevated 15 degrees. The bag was then unfolded by transiently inflating it with 75 ml of air. The catheter was connected to a barostat (G&J Electronics Inc., Toronto, Ontario, Canada) and the pressure in the bag was increased from 4 mmHg in steps of 1 mmHg for 1 minute per step until respiratory excursions were observed. The baseline operating pressure was defined as 2 mmHg above the minimal distension pressure at which respiratory excursions were clearly recorded from the barostat tracing. An initial “conditioning” distension of the rectum was performed with pressure increased from 0 to
Page 10 of 32
Camilleri
10
20 mmHg in steps of 4 mmHg for 15 seconds per step. This renders subsequent assessments of compliance and perception more reproducible (20). The bag was then deflated to 0 mmHg and the subjects were allowed to rest for 10 minutes. Rectal sensory thresholds were measured by ramp inflation, starting at 0 mmHg and increasing in steps of 4 mmHg for 1 minute per step to a maximum of 60 mmHg. Thresholds for first sensation, gas, urgency, and pain were indicated by the subjects pressing a button at the distension pressure at which sensations were perceived. Ramp inflation was terminated when the subjects reported the first sensation of pain. Following this procedure, the bag was deflated to the baseline operating pressure and the subjects were allowed to rest for 10 minutes. Rectal sensory ratings were measured using phasic distensions of 12, 24, 30 and 36 mmHg above baseline operating pressure applied once in random order. The order was provided by the study statistician (ARZ). Each distention was maintained for 60 seconds with an inter-stimulus interval of 2 minutes, during which time the balloon was deflated to the baseline operating pressure. Subjects were asked to mark separate 100 mm visual analog scales (VAS) 30 seconds after the onset of the distension for the sensations of gas, urgency, and pain. These scales were anchored at the ends by the descriptions ‘unnoticeable’ and ‘unbearable’. Pressure was released if the subject reported greater than 80 mm of pain on the VAS scale, and higher distensions were not subsequently administered. Immediately prior to the sensory testing the participants filled in 100 mm VAS assessing their current state of “tiredness”, “worry”, “peace”, and “activity”.
Page 11 of 32
Camilleri
11
The following measurements were derived: (i) the sensory thresholds for first sensation, gas, urgency, and pain during ascending method of limits and (ii) the gas, urgency, and pain scores in response to the four random phasic distensions (12, 24, 30 and 36 mmHg above baseline operating pressure) delivered in randomized order according to a scheme generated by the study statistician and communicated to the technologist on the day of the sensation test. FAAH Genotyping FAAH genotype was determined by an investigator (PC) blinded to all clinical information using TaqMan® SNP genotyping assays (Applied Biosystems, CA) and confirmed by direct sequencing of representative samples. We adapted the approach previously published by Sipe et al. (33) in which primers were designed for the FAAH 385 wildtype C and mutant A alleles. Statistical Analysis The statistical analysis assessed the overall association of genotype with symptom phenotype using contingency table analyses (
2
test), combining all FGIDs into one group
and separately using the individual FGID subtypes. Odds ratios for each symptom phenotype (compared to controls) in FAAH CA/AA (relative to CC) were estimated using multiple logistic regression, adjusting for age and gender. Association of genotype with GI motor function was assessed using analysis of covariance (ANCOVA), adjusting for age, gender, BMI and symptom phenotype (including healthy controls). The analysis of rectal sensation thresholds used proportional hazards regression models separately for each threshold type (first sensation, gas, urgency and pain) incorporating HAD scores for anxiety and depression (40), BMI, and somatic symptom checklist score as covariates.
Page 12 of 32
Camilleri
12
The analysis of the sensation VAS ratings scores used repeated measures ANCOVA models (multiple pressure distension levels as the repeated factor) separately for gas, urgency and pain sensation types, and included the HAD scores, somatic symptom checklist score, BMI , SCL-90 somatization scale (15), and the scores for “tired”, “worried”, “peace”, and “activity” during the sensation test as covariates. Along with the main effects terms for phenotype and genotype, these models also included a genotype by phenotype interaction term. Post-hoc pairwise comparisons of genotype subgroups within each phenotype were also examined. RESULTS Demographics and Distribution of FAAH Genotype Participant demographics are included in Table I. Genotype distribution did not deviate significantly from Hardy–Weinberg equilibrium at the polymorphic locus. The distribution of CC/CA/AA genotype in the healthy controls was similar to that reported in other predominantly Caucasian controls [(18,23) Fig. 1], that is, approximately 60:30:5. Association of Genotype with Symptom Phenotype There was a significant association of genotype with overall FGID phenotype in comparison to healthy controls (p=0.011,
2
). There was also a significant association
between FAAH genotype and individual phenotype (p= 0.048, Fig. 2); thus, the odds for FGID sub-phenotype (compared to health) were increased in FAAH CA/AA (relative to CC) in D-IBS (p=0.008) and M-IBS (p=0.012). The association with chronic abdominal pain was not statistically significant (p=0.055). Odds ratios from the logistic regression model were adjusted for age and gender.
Page 13 of 32
Camilleri
13
Association of Genotype with Motility Phenotype There was no significant overall association of FAAH genotype with GI motor function (Table II, analysis of covariance adjusting for age, gender, and BMI). However, there was a significant association with colonic transit (GC at 24 hours) in D-IBS (p=0.037), that is, FAAH CA/AA genotype was associated with accelerated colonic transit compared to FAAH CC genotype in patients with D-IBS. There was no significant association of FAAH genotype and gastric emptying (Fig. 3); on the other hand, the gastric accommodation volume (Fig. 4) appears to be possibly influenced by the FAAH genotype in dyspepsia (p=0.057). Association of Genotype with Sensation Phenotype There was no significant overall association of FAAH genotype with rectal sensation thresholds (Table IIIA) or rectal sensory ratings (Table IIIB) in response to random order distensions. No interaction effects were detected, indicating lack of associations between FAAH genotype and sensory ratings within different IBS phenotypes and healthy controls. DISCUSSION Our single-center study presents a number of novel perspectives. The study explored the association between genetic variation in endocannabinoid metabolism that controls, in part, CB1 receptor modulation and the occurrence of functional gastrointestinal disorders and the associated changes on motor or sensory functions. The significant associations of FAAH genotype with M-IBS and D-IBS symptoms and with colonic transit in D-IBS are consistent with the knowledge that CB1 receptor modulation alters colonic smooth muscle contraction and alters colonic tone and phasic contractions
Page 14 of 32
Camilleri
14
in vivo in humans (16,21). These results support the hypothesis that genetic metabolism of endocannabinoids is associated with symptom phenotype in IBS and colonic transit in D-IBS. Our study in humans, in principle, is comparable to the use of knockout animals to demonstrate the importance of a certain mechanism through the observation of a certain function or phenotype. Knockout or silencing approaches are possible in experimental animals, but not in humans. Thus, we use the natural variation in the genes controlling FAAH enzyme in humans to assess whether this genetic variation impacts on the phenotype of interest, and infer that cannabinoid mechanisms might be involved in the generation of that phenotype. The association between genotype variation (non-wildtype CA or AA FAAH genotypes) in endocannabinoid metabolism by FAAH and colonic transit at 24 hours in patients with D-IBS is concordant with the association with D-IBS or M-IBS symptom phenotype. This concordance supports the general hypothesis that endocannabinoids may be relevant to the control of mechanisms that result in symptoms of IBS and alteration in colonic motor function. The observation of accelerated colonic transit and phenotypes that include diarrhea suggest that, if the non-wild type (CA/AA) genotype results in reduced expression of FAAH, the increased anandamide may ultimately block the release of transmitter from pre-junctional inhibitory neurons (reviewed in reference 38). Similarly, it has been demonstrated that the CB1 agonist, WIN55212-2, causes a presynaptic depression of GABAergic inhibitory postsynaptic currents (IPSCs) in hippocampal slices (19,22), and reduces GABA release from the presynaptic boutons of local interneurons in the rostral ventromedial medulla (36).
Page 15 of 32
Camilleri
15
Cannabinoid mechanisms may be relevant to several of the putative mechanisms of FGID. For example, IBS is associated with visceral hypersensitivity (6), and animal models of acute or chronic pain support a role of cannabinoid mechanisms in control of nociception in pain models, including that associated with gut inflammation (26,30,32). CB1 immunoreactivity is located on normal colonic epithelium, smooth muscle, and the myenteric plexus, whereas CB1 and CB2 receptors are expressed in plasma cells (39). IBS is associated with colonic motor dysfunction (6). In mice, endocannabinoids acting on myenteric CB1 receptors tonically inhibit colonic propulsion (31), and activation of CB1 receptors coupled to cholinergic motor neurons inhibits excitatory nerve transmission in human colonic circular muscle in vitro (21). A non-specific CB receptor agonist, dronabinol, inhibits human gastric and colonic motor function in vivo (16,17). The cannabinoid system also modulates immune function and inflammation (32), and this may be relevant in a subset of patients with FGIDs (6). CB1 and CB2 receptor activation occurs in an experimental model of colitis induced by oil of mustard (25), and anti-inflammatory effects of cannabinoids may involve cytokines, chemokines, modulation of adenosine signaling (9), expression of adhesion molecules, and the migration, proliferation, and apoptosis of inflammatory cells (26,37). Given these findings, future studies should also explore the potential role of cannabinoid mechanisms in the inflammatory component of IBS. Strengths
While the current study used a large database (almost 750) of well-characterized patients and healthy volunteers in a single center, as well as validated questionnaires and measurements of gastric and colonic functions, the results should be viewed as only hypothesis-generating, given the retrospective analysis of the healthy volunteers and
Page 16 of 32
Camilleri
16
FGID patients who had participated in other studies that evaluated gastric and colonic motor and sensory functions, as well as the relatively small sample sizes of some of the patient groups. Thus, it is possible that type II errors may contribute to the nonsignificant associations between FAAH variation and gastric volume in dyspepsia (n=23, p=0.06), and the odds ratio for an association between FAAH variation (as shown in Fig. 4) and CAP (n= 20, p=0.055, as shown in Fig. 2). The present data provide information that is useful to plan future studies to test the general hypothesis that FAAH presents a functionally relevant genetic variation in the control of gastrointestinal motor and sensory functions. Given the results in the present study, it would seem reasonable to focus on D-IBS and colonic transit and, possibly, on gastric accommodation in functional dyspepsia, especially the postprandial distress syndrome subgroup. There is biological evidence of functional relevance of this same genetic variation in the association with drug abuse and with overweight and obesity in Caucasians and African-Americans (33,34). Limitations
Despite the fact that this sample is larger than any other prior study of genetic association with symptom phenotype in the IBS literature and is the first seeking an association between genotype and physiological phenotpyes, a limitation of our study is that the prevalence of the homozygous A (AA) genotype is too small (5%) to allow an independent assessment of the association of AA genotype with phenotypes or motor functions with the sample size available. Therefore, a follow-up study is needed to determine whether AA genotype alters colonic transit relative wildtype (CC) genotype. Another limitation is that it is unclear whether the heterozygous (CA) genotype reduces FAAH protein expression or function.
Page 17 of 32
Camilleri
17
The only genetic modulation in the cannabinoid system assessed in this study pertains to the metabolism of the endocannabinoid, anandamide. The rationale for this choice was based on the prior literature showing functional significance of the genetic variant of FAAH (11) and the fact that, among the 13 SNPs in FAAH gene, the only one with a functional effect is the C385A ( rs324420). By way of contrast, NCBI records >120 SNPs in the MGLL gene, which encodes for the rate limiting enzyme monoacyl glycerol lipase (MAGL) for metabolism of 2-arachidonoyl glycerol, another endocannabinoid. Of these >120 SNPs, two are non-synonymous SNPs, whereas the rest are synonymous or intronic up- or down-stream from the gene. The two nonsynonymous genes are designated rs11538700 and rs1804711. In NCBI databases, there are no data on allelic distribution for rs1804711; for rs11538700, 58 European Caucasians, 44 Asians, and 58 sub-Saharan Africans showed no allelic changes, that is, all participants showed the TT genotype. Similarly, in reviewing the genetic variation in CNR1 (the gene for CB1 receptor), there are only two synonymous SNPs, rs35057475 and rs1049353. In NCBI, allelic frequency of rs35057475 has been reported for only 24 European Caucasians (A/G=0.026, G/G=0.974), and rs1049353 has been reported in 38 African Americans (A/G= 0.458; G/G=0.542). For rs35057475, there were no homozygotes of the minor allele; for rs1049353, the minor allele frequency is 5%. There is an (AAT) repeat at the 3’ end of CNR1, 18,000 bases downstream from the start site of exon 4 of CNR1. The literature shows that the number of repeats is highly variable and, although, associations with psychiatric disease, i.v. drug use, and response to antipsychotics have been described (2,3,12,28,35), the functional significance of the genetic variation is unclear.
Page 18 of 32
Camilleri
18 CONCLUSION
In summary, FAAH genotype variation in the metabolism of endocannabinoids is associated with symptom phenotype in IBS and colonic transit in D-IBS. The effects of this genetic variation on gut function and responses to cannabinoid modulation deserve further study, including studies of familial associations of the genotype with symptoms suggestive of FGID in the apparently healthy relatives of IBS patients. In this study, we observed no statistically significant association between FAAH genotype and sensation measurements in IBS or health. However, further investigation of these mechanisms will be required using exogenous agents modulating CB receptor on models of visceral pain in patients with IBS in order to more fully characterize the potential therapeutic effects of cannabinoid agents. Competing Interests None to declare.
Page 19 of 32
Camilleri
19 REFERENCES
1.
Andresen V, Camilleri M, Kim HJ, Stephens DA, Carlson PJ, Talley NJ, Saito
YA, Urrutia R, Zinsmeister AR. Is there an association between GN 3 C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 130: 19851994, 2006. 2.
Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, Poirier
MF. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 6: 126-130, 2006. 3.
Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J,
Hoenicka J, Garcia Yebenes J. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 5: 135141, 2005. 4.
Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde
GM, Chial HJ. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 51: 781-786, 2002. 5.
Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit
scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 38: 1807-1810, 1997. 6.
Camilleri M. Editorial: Mechanisms in IBS: something old, something new,
something borrowed…. Neurogastroenterol Motil 17: 311-316, 2005.
Page 20 of 32
Camilleri 7.
20
Camilleri CE, Carlson PJ, Camilleri M, Castillo EJ, Locke GR III, Geno DM,
Stephens DA, Zinsmeister AR, Urrutia R. A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterology 101: 581-592, 2006. 8.
Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive,
accurate test for colonic motility disorders. Gastroenterology 103: 36-42, 1992. 9.
Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside
transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895–7900, 2006. 10.
Castillo EJ, Camilleri M, Locke GR III, Burton DD, Stephens DA, Geno DM,
Zinsmeister AR. A community based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2: 985-996, 2004. 11.
Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and
activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13: 2113-2119, 2004. 12.
Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G,
MacMurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 2: 161-168, 1997. 13.
Cremonini F, Houghton LA, Camilleri M, Ferber I, Fell C, Cox V, Castillo EJ,
Alpers DH, Dewit OE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 17: 810-820, 2005.
Page 21 of 32
Camilleri 14.
21
Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance
characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 16: 1781-1790, 2002. 15. Derogatis LR, Rickels K, Rock A. The SCL-90 and the MMPI: A step in the validation of a new self-report scale. Br J Psychiatry 128: 280–290, 1976. 16.
Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR.
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol 293: G137-145, 2007. 17.
Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR.
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 18: 831-838, 2006. 18.
Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide
hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 120: 581-588, 2006. 19. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249, 2000. 20.
Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility,
and perception: reproducibility and response to different distensions. Am J Physiol 274: G584-590, 1998.
Page 22 of 32
Camilleri 21.
22
Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to
cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 148: 191-199, 2006. 22. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479, 2000. 23. http://www.ncbi.nlm.nih.gov/About/disclaimer.html 24.
Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D,
McKinzie S, Zinsmeister AR, Urrutia R. Association of distinct
2
adrenoceptor and
serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 53: 829-837, 2004. 25.
Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid
receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol 291: G364-G371, 2006. 26.
Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev
Immunol 5: 400–411, 2005. 27.
Kuiken SD, Samsom M, Camilleri M, Mullan BP, Burton DD, Kost LJ,
Hardyman TJ, Brinkmann BH, O'Connor MK. Development of a test to measure gastric accommodation in humans. Am J Physiol 277: G1217-G1221, 1999. 28.
Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez-
Arriero MA, Perez-Hernandez E, Ampuero I, Ramos-Atance JA, Palomo T, Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 256: 437-441, 2006.
Page 23 of 32
Camilleri 29.
23
O'Connor MK, O'Connell R, Keane FB, Byrne PJ, Hennessy TP. The
relationship between technetium 99m pertechnetate gastric scanning and gastric contents. Br J Radiol 56: 817-822, 1983. 30.
Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target
of pharmacotherapy. Pharmacol Rev 58: 389-462, 2006. 31.
Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR,
Mascolo N, Di Marzo V, Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234, 2002. 32.
Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in
inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 18: 949-956, 2006. 33.
Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in
human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99: 8394-8399, 2002. 34.
Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with
a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 29: 755-759, 2005. 35.
Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene
(CNR1) polymorphism and schizophrenia. Psychiatr Genet 10: 149-151, 2000. 36. Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127: 935-940, 1999.
Page 24 of 32
Camilleri 37.
24
Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 141:
775–785, 2004. 38.
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 296: 678–
682, 2002. 39.
Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S.
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453, 2005. 40.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand ;67: 361-370, 1983.
Page 25 of 32
Camilleri Table I.
25 Participant Demographics. Note that, for the genotype subgroups, data are
pooled for FGID patients and healthy volunteers.
Subgroup
N
Gender: F:M
Mean + SD
IBS-C/ Functional Constipation
159
152:7
45.08 + 14.39
IBS-D/ Functional diarrhea
184
153:31
45.16 + 15.24
IBS-M
86
79:7
41.01 + 13.31
Chronic abdominal pain
20
14:6
46.55 + 15.77
Functional Dyspepsia
33
13:20
52.545 + 11.53
All FGID
482
411:71
44.95 + 14.60
Healthy volunteers
252
185: 67
36.62 + 12.43
FAAH CC
464
378:86
42.40 + 14.41
FAAH CA/AA
270
218:52
41.57 + 14.51
Page 26 of 32
Camilleri Table II.
26 Association of FAAH Genotype with Gastrointestinal Motor Functions. Note
that analysis of covariance adjusting for age, gender, and BMI showed no significant effect of genotype on the gastrointestinal motor functions of interest in the entire participant pool not separated by phenotype.
Genotype
Gastric emptying at 2h, %
Gastric emptying at 4h, %
Fasting gastric volume, mL
Colonic transit, GC at 24h
Colonic transit, GC at 48h
233 + 10
Postprandi al gastric volume, mL 497 + 10
CC
53.1 + 1.8
93.9 + 1.0
2.82 + 0.17
3.88 + 0.16
CA/AA
55.0 + 2.0
95.4 + 1.1
228 + 11
509 + 13
2.48 + 0.17
3.65 + 0.17
Page 27 of 32
Camilleri
Table III.
27
Relationship between FAAH Genotype and Sensory Thresholds for Rectal Sensation and Rectal Sensory Ratings of Gas,
Urgency and Pain in Response to Rectal Distensions. Note there are no significant differences in either median thresholds or sensory ratings in healthy participants or patients with IBS who underwent rectal sensation studies (total n=123) A. Data show median threshold value in mmHg. group C-IBS C-IBS D-IBS D-IBS M-IBS M-IBS Health Health
N 25 13 15 12 12 13 21 11
FAAH genotype CC CA/AA CC CA/AA CC CA/AA CC CA/AA
First sensation 8 8 8 6 6 8 8 8
Gas 16 12 12 10 12 12 8 8
Urgency 20 24 20 16 14 16 16 16
Pain 36 20 28 24 24 32 24 24
B. Data show sensory ratings (mean + SEM) in response to standard pressure distensions using random order phasic distensions (mmHg above baseline operational pressure). GAS pressure, mm Hg CC FAAH, n=73 CA/AA FAAH, n=50
URGENCY 24 30
12
24
30
36
12
40.0+2.7
54.3+3.4
59.0+3.6
60.1+4.0
42.8+2.6
64.1+2.8
41.1+3.1
54.3+3.4
59.0+3.6
60.1 +4.0
47.4+2.9
65.3+2.6
PAIN 36
12
24
30
36
72.3+2.4
77.8+2.3
26.2+2.5
44.7+3.0
53.0+2.9
56.3+3.1
74.2+2.6
74.9+3.0
31.8+3.5
52.0+3.8
58.2+4.0
61.4+3.9
Page 28 of 32
Camilleri
28
FIGURE LEGENDS Figure 1.
FAAH genotype distribution in FGID patients and healthy controls studied at
Mayo Clinic and reported distribution in National Center for Biotechnology Information (NCBI) and a study conducted predominantly in Caucasians. Figure 2.
Odds ratios and 95% confidence intervals for FGID sub-phenotypes
(compared to health) are increased in FAAH CA/AA genotype relative to homozygous C genotype. Figure 3.
Association of FAAH genotype with gastric emptying at 4 h (upper), colonic
transit at 24 h (lower) in different subgroups of FGID. Note the significantly faster colonic transit at 24 h in D-IBS patients with CA/AA genotype compared to CC genotype. Figure 4. Association of FAAH genotype with fasting (upper) and postprandial change in gastric volumes (lower) in different subgroups of FGID. Note the suggestion of an association of the same genotype with greater change in gastric volume postprandially in patients with functional dyspepsia.
Page 29 of 32
Page 30 of 32
Page 31 of 32
Page 32 of 32
